改良FOLFIRINOX方案治疗进展期胰腺癌的临床疗效

发布时间：2018-05-28 10:48

  本文选题：FOLFIRINOX + 胰腺癌　； 参考：《浙江大学》2017年硕士论文

【摘要】：目的:评估改良FOLFIRINOX方案治疗进展期胰腺癌的临床疗效和安全性。方法:本研究共纳入2014年4月至2016年12月在本中心接受改良FOLFIRINOX(modified-FOLFIRINOX,mFOLFIRINOX)(无 5-氟尿嘧啶静推,80%原剂量奥沙利铂,75%原剂量伊立替康)化疗的进展期胰腺癌(advanced pancreatic cancer,APC)患者68例(LAPC 28例,MPC 40例),评估mFOLFIRINOX方案化疗后的缓解率、安全性、转化率、手术信息、整体生存率、无进展生存时间等。结果:68例APC患者对mFOLFIRINOX方案化疗总体反应率为26.5%;最常见的3/4级副反应为中性粒细胞减少(26.5%)和贫血(14.75%);化疗后11例LAPC实现转化并接受了手术(转化率39.3%);LAPC组病人中位生存时间(overall survival,OS)和无进展生存时间(progression free survival,PFS)均为 13 个月,MPC组中位生存时间和中位无进展生存时间分别为10个月和9个月。结论:本中心应用mFOLFIRINOX化疗方案能显著改善中国APC人群的对化疗药毒副反应的耐受性,同时保持与原方案方案相仿的疗效和让人可接受的毒性反应发生率。这些数据可能为FOLFIRINOX在中国用于治疗进展期胰腺癌患者提供指导。
[Abstract]:Objective: to evaluate the efficacy and safety of modified FOLFIRINOX regimen in the treatment of advanced pancreatic cancer. Methods: from April 2014 to December 2016, 68 patients with advanced pancreatic cancer of advanced pancreatic cancer received modified FOLFIRINOXX modified FOLFIRINOXMFOLFIRINOXX (no 5-fluorouracil 80% oral oxaliplatin 75% primordial dose of Ilitecan) in our center from April 2014 to December 2016 were enrolled in this study. The remission rate of 28 patients with MPC was evaluated after chemotherapy with mFOLFIRINOX regimen (n = 40). Safety, conversion rate, surgical information, overall survival rate, progression-free survival time, etc. Results the overall response rate of 68 patients with APC to mFOLFIRINOX regimen was 26.5; the most common side effects of grade 3 / 4 were neutropenia 26.5) and anemia 14.7550. After chemotherapy, 11 cases of LAPC were transformed and underwent surgery (the conversion rate was 39.3%) and the median survival rate of the patients in the LAPC group was 39.3%. The median survival time and progression free survival time of MPC group were 10 months and 9 months, respectively. Conclusion: mFOLFIRINOX regimen in our center can significantly improve the tolerance to side effects of chemotherapy in Chinese APC population, while maintaining the same efficacy and acceptable incidence of toxic reactions as the original regimen. These data may provide guidance for the use of FOLFIRINOX in the treatment of advanced pancreatic cancer in China.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.9
，

本文编号：1946413